An indirect comparison of GLP-1 RAs and SGLT-2 inhibitors, administered daily or weekly, did not reveal significant differences in the risks of MACE in T2DM patients with obesity. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.